Cover Image

The Impact of Glucagon-Like Peptide 1 Receptor Agonists on Bone Metabolism and Its Possible Mechanisms in Osteoporosis Treatment

Diabetes mellitus and osteoporosis are closely related and have complex influencing factors. The impact of anti-diabetic drugs on bone metabolism has received more and more attention. Type 2 diabetes mellitus (T2DM) would lead to bone fragility, high risk of fracture, poor bone repair and other bone...

Full description

Saved in:

Bibliographic Details
Main Authors:	Baocheng Xie (Author), Shichun Chen (Author), Yongxiang Xu (Author), Weichao Han (Author), Runkai Hu (Author), Minyi Chen (Author), Yusheng Zhang (Author), Shaobo Ding (Author)
Format:	Book
Published:	Frontiers Media S.A., 2021-06-01T00:00:00Z.
Subjects:	article
Online Access:	Connect to this object online.
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Clinical Efficacy and Safety of Human Mesenchymal Stem Cell Therapy for Degenerative Disc Disease: A Systematic Review and Meta-Analysis of Randomized Controlled Trials
by: Baocheng Xie, et al.
Published: (2021)

Therapeutic Evidence of Human Mesenchymal Stem Cell Transplantation for Cerebral Palsy: A Meta-Analysis of Randomized Controlled Trials
by: Baocheng Xie, et al.
Published: (2020)

Glucagon-like peptide-1 and glucagon-like peptide-1 receptor agonists in the treatment of type 2 diabetes
by: Seungah Lee, et al.
Published: (2017)

Epimedin C Alleviates Glucocorticoid-Induced Suppression of Osteogenic Differentiation by Modulating PI3K/AKT/RUNX2 Signaling Pathway
by: Yongxiang Xu, et al.
Published: (2022)

Possible Mechanisms Underlying the Effects of Glucagon-Like Peptide-1 Receptor Agonist on Cocaine Use Disorder
by: Changliang Zhu, et al.
Published: (2022)

Glucagon-like peptide-1 (GLP-1) agonists in the treatment of obesity
by: Magdalena Mazurek, et al.
Published: (2023)

Pharmacoeconomic characteristics of agonists of receptors for glucagon-like peptide-1 and medicines on their base
by: I. N. Dyakov, et al.
Published: (2021)

Glucagon-like peptide-1 receptor co-agonists for treating metabolic disease
by: Laurie L. Baggio, et al.
Published: (2021)

Glucagon-like peptide-1 receptor agonists and derivatives in the treatment of obesity - review
by: Michal Rabenda, et al.
Published: (2024)

Effect of Glucagon-like peptide-1 receptor agonists on dyslipidemia in type 2 diabetes
by: Elizabeth A. Cristiano, et al.
Published: (2020)

Impact of Glucagon-like Peptide-1 Receptor Agonists on Intestinal Epithelial Cell Barrier
by: Takizawa Y., et al.
Published: (2024)

The Therapeutic Potential of Glucagon-like Peptide 1 Receptor Agonists in Traumatic Brain Injury
by: Anja Harej Hrkać, et al.
Published: (2024)

Amelioration of muscle wasting by glucagon‐like peptide‐1 receptor agonist in muscle atrophy
by: Yeonhee Hong, et al.
Published: (2019)

Glucagon-like peptide-1 receptor agonists as add-on therapy to insulin for type 1 diabetes mellitus
by: Xinrui Tan, et al.
Published: (2023)

Health Technology Assessment: Evaluation of 7 Glucagon-Like Peptide-1 Receptor Agonists for the Treatment of Type 2 Diabetes Mellitus
by: Xie Z, et al.
Published: (2024)

Glucagon-like peptide-1 receptor agonists: new strategies and therapeutic targets to treat atherosclerotic cardiovascular disease
by: Tianyu Wang, et al.
Published: (2024)

Potential Roles of Glucagon-Like Peptide 1 Receptor Agonists (GLP-1 RAs) in Nondiabetic Populations
by: Dan Xu, et al.
Published: (2022)

Effects of glucagon-like peptide 1 receptor agonists on comorbidities in older patients with diabetes mellitus
by: Olusola F. Onoviran, et al.
Published: (2019)

Glucagon-like peptide-1 receptor agonists for treatment of diabetes and obesity: advantage of oral delivery
by: R. R. C. New, et al.
Published: (2024)

Possibilities of using analogues of glucagon-like peptide-1 in various disease entities
by: Weronika Bielka, et al.
Published: (2021)

Glucagon-like peptide receptor agonists attenuate advanced glycation end products-induced inflammation in rat mesangial cells
by: Jui-Ting Chang, et al.
Published: (2017)

Glucagon-Like Peptide-1 Receptor Agonists and Dual Glucose-Dependent Insulinotropic Polypeptide/Glucagon-Like Peptide-1 Receptor Agonists in the Treatment of Obesity/Metabolic Syndrome, Prediabetes/Diabetes and Non-Alcoholic Fatty Liver Disease-Current Evidence
by: Emir M. Muzurović MD, MM, et al.
Published: (2022)

Economic analysis of glucagon like peptide-1 receptor agonists from the Saudi Arabia payer perspective
by: Nimer S. Alkhatib, et al.
Published: (2022)

The Impact of Glucagon-like Peptide 1 Receptor Agonists on Obstructive Sleep Apnoea: A Scoping Review
by: Khang Duy Ricky Le, et al.
Published: (2024)

An Effective Glucagon-Like Peptide-1 Receptor Agonists, Semaglutide, Improves Sarcopenic Obesity in Obese Mice by Modulating Skeletal Muscle Metabolism
by: Ren Q, et al.
Published: (2022)

Hypersensitivity to glucagon‐like peptide‐1 receptor agonists: A case of delayed urticaria‐like rash to dulaglutide and literature review
by: Leonardo Bianchi, et al.
Published: (2024)

Glucagon-like peptide 1 (GLP-1)
by: T.D. Müller, et al.
Published: (2019)

Glucagon-like peptide-1 receptor agonists in diabetic kidney disease: A review of their kidney and heart protection
by: Erin D. Michos, et al.
Published: (2023)

The Role of Glucagon-Like Peptide-1 Receptor Agonists (GLP-1 RA) in Diabetes-Related Neurodegenerative Diseases
by: Cheng D, et al.
Published: (2022)

Clinical Impact of Semaglutide, a Glucagon-Like Peptide-1 Receptor Agonist, on Obesity Management: A Review
by: Alorfi NM, et al.
Published: (2022)

Amelioration of inflammatory myopathies by glucagon‐like peptide‐1 receptor agonist via suppressing muscle fibre necroptosis
by: Mari Kamiya, et al.
Published: (2022)

A Comprehensive Review on Weight Gain following Discontinuation of Glucagon-Like Peptide-1 Receptor Agonists for Obesity
by: Ibrahim Abdullah bin Ahmed
Published: (2024)

A Health Technology Assessment Based on Chinese Guidelines: Glucagon-Like Peptide-1 Receptor Agonist in the Treatment of Type 2 Diabetes Complicated with Cardiovascular Disease
by: Xie Z, et al.
Published: (2022)

Effect of gut hormones on bone metabolism and their possible mechanisms in the treatment of osteoporosis
by: Hongyu Liu, et al.
Published: (2024)

Glucagon-like peptide-1 receptor agonists rescued diabetic vascular endothelial damage through suppression of aberrant STING signaling
by: Xuemin He, et al.
Published: (2024)

Effect of glucagon-like peptide-1 (GLP-1) agonists on the example of semaglutide on the cardiovascular system and their role in the treatment of obesity.
by: Kamil Pondel, et al.
Published: (2022)

Disconnect between signalling potency and in vivo efficacy of pharmacokinetically optimised biased glucagon-like peptide-1 receptor agonists
by: Maria Lucey, et al.
Published: (2020)

Potential Role of Phytochemicals as Glucagon-like Peptide 1 Receptor (GLP-1R) Agonists in the Treatment of Diabetes Mellitus
by: Julianah Ore Abiola, et al.
Published: (2024)

Perioperative Glucagon-Like Peptide-1 Receptor Agonists (GLP-1RA) and Gastric Point Of Care Ultrasound (POCUS)
by: Sivasenthil Arumugam, et al.
Published: (2024)

Physiology and pharmacology of glucagon-like peptide-1 receptor
by: D. V. Kurkin, et al.
Published: (2024)